Evaluation of the efficacy of bivalos in the treatment of postmenopausal osteoporosis in type 2 diabetes

Abstract

The purpose of the Investigation was to study the efficacy and tolerability of Bivalos in the treatment of postmenopausal osteoporosis (OP) in women with type 2 diabetes mellitus (DM-2). Twenty-nine women with OP verified by the DEXA test at the age of above 50 years who had a postmenopause and a verified diagnosis of DM-2 were examined. After examination comprising the determination of blood calcium and phosphorus, glycated hemoglobin, glycemia on an empty stomach and two hours after a meal, testing with the European quality of life questionnaire EQ-5D, evaluation of the natural history of pain syndrome by a 100-ml visual analog scale, the patients were given osteoporosis therapy with Bivalos, 2g/day, Calcium D₃ ^Nikomed, 2 tablets daily. Reexamination was made following 12 months. A significantly higher bone mineral density was revealed in both the lumbar (by 6%) and distal (by 5.6%) segments of the femur. At the same time, there was a reduction in 85.7% of the patients with pain syndrome, the quality of life improved in 51.7% of the females. Bivalos was well tolerated by patients with DM-2; adverse reactions occurred rarely, regressed sufficiently rapidly, and required no drug discontinuance. The findings have led to the conclusion that the use of Bivalos is safe and effective in patients with comorbidity (postmenopausal OP and DM-2).